ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.7% – What’s Next?

ADMA Biologics Inc (NASDAQ:ADMA)’s share price fell 8.7% during trading on Tuesday . The stock traded as low as $12.41 and last traded at $12.4080. Approximately 4,620,968 shares changed hands during trading, an increase of 53% from the average session volume of 3,028,221 shares. The stock had previously closed at $13.59.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ADMA. Wall Street Zen upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $32.00.

ADMA Biologics Trading Down 16.6%

The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $2.70 billion, a PE ratio of 18.88 and a beta of 0.51. The stock’s fifty day simple moving average is $16.25 and its 200 day simple moving average is $16.61.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The firm had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same quarter in the previous year, the firm posted $0.46 EPS. The company’s revenue for the quarter was up 18.4% compared to the same quarter last year. On average, sell-side analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the transaction, the chief operating officer directly owned 466,600 shares in the company, valued at $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steve Elms acquired 7,000 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was acquired at an average cost of $15.67 per share, with a total value of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADMA. Quadrant Capital Group LLC raised its position in shares of ADMA Biologics by 3.9% during the second quarter. Quadrant Capital Group LLC now owns 16,660 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 629 shares during the last quarter. Lido Advisors LLC grew its stake in ADMA Biologics by 3.8% during the fourth quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock valued at $312,000 after acquiring an additional 629 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in ADMA Biologics by 11.7% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 634 shares in the last quarter. Cim LLC increased its holdings in ADMA Biologics by 0.7% in the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock valued at $1,341,000 after acquiring an additional 665 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in ADMA Biologics by 28.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 700 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.